ANKRD28: A Potential Drug Target and Biomarker (G23243)

Target Name: ANKRD28

NCBI ID: G23243

ANKRD28

ANKRD28: A Potential Drug Target and Biomarker

Ankyrin repeat domains (ARDs) are a class of non-coding RNA molecules that have been identified as potential drug targets in various diseases. ANKRD28, a member of the ARD family, has been identified as a potential drug target and biomarker in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

The ANKRD28 gene is located on chromosome 14q21 and has 21 exons. It encodes a protein that consists of 154 amino acid residues. The protein has a calculated molecular weight of 19.9 kDa and a predicted localization in the cell as a protein that is predominantly expressed in the brain and spinal cord.

The ANKRD28 protein is involved in various cellular processes, including cell adhesion, migration, and survival. It has been shown to be involved in the regulation of neural cell survival and has been implicated in the development and progression of neurodegenerative disorders.

ANKRD28 has also been shown to be involved in the regulation of cancer cell growth and has been identified as a potential biomarker for cancer. In addition, ANKRD28 has been implicated in the regulation of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis.

Due to its involvement in various cellular processes and its potential as a drug target, ANKRD28 has received a great deal of interest in recent years. Several studies have investigated the effects of ANKRD28 antagonists on various cellular processes, including cell adhesion, migration, and survival. These studies have led to the conclusion that ANKRD28 plays an important role in the regulation of cellular processes and that its disruption may contribute to the development of various diseases.

In addition to its potential as a drug target, ANKRD28 has also been shown to be a potential biomarker for several diseases. Its involvement in the regulation of neural cell survival and its potential as a drug target make it an attractive candidate for the development of diagnostic tools and therapies for neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

ANKRD28 has also been shown to be involved in the regulation of cancer cell growth and has been identified as a potential biomarker for cancer. The disruption of ANKRD28 has been shown to have a negative impact on cancer cell growth and survival, leading to the conclusion that ANKRD28 may be a useful biomarker for the diagnosis and treatment of cancer.

In addition to its potential as a drug target and biomarker, ANKRD28 is also of interest as a potential therapeutic target. The regulation of ANKRD28 has been shown to play an important role in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The disruption of ANKRD28 has been shown to contribute to the progression of these disorders, leading to the conclusion that ANKRD28 may be a useful target for the development of therapeutic interventions.

In conclusion, ANKRD28 is a protein that has been shown to be involved in various cellular processes and has potential as a drug target and biomarker in various diseases. Its involvement in the regulation of cellular processes and its potential as a drug target and biomarker make it an attractive candidate for the development of diagnostic tools and therapies for neurodegenerative disorders, cancer, and autoimmune diseases. Further research is needed to fully understand the role of ANKRD28 in these diseases and to develop effective therapeutic interventions.

Protein Name: Ankyrin Repeat Domain 28

Functions: Putative regulatory subunit of protein phosphatase 6 (PP6) that may be involved in the recognition of phosphoprotein substrates. Involved in the PP6-mediated dephosphorylation of NFKBIE opposing its degradation in response to TNF-alpha. Selectively inhibits the phosphatase activity of PPP1C. Targets PPP1C to modulate HNRPK phosphorylation

The "ANKRD28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets